The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages

British Journal of Pharmacology

Volumn 161, Issue 3, 2010, Pages 555-570

  Rossi, Antonietta ^a,b   Pergola, C ^a,c   Koeberle, A ^c   Hoffmann, M ^d   Dehm, F ^a,c   Bramanti, P ^b   Cuzzocrea, S ^b,e   Werz, O ^c   Sautebin, L ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF MESSINA   (Italy)

Author keywords

5 lipoxygenase; cyclooxygenase; leukotrienes; lipopolysaccharide; macrophages; prostaglandins

Indexed keywords

ARACHIDONIC ACID; CARRAGEENAN; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; PHOSPHOLIPASE A2; PROSTAGLANDIN; ZILEUTON; ZYMOSAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; NONHUMAN; NORMAL HUMAN; PERITONEUM MACROPHAGE; PLEURISY; PRIORITY JOURNAL; RAT;

EID: 77956309955     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00930.x     Document Type: Article

References (38)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254.
2. Beierschmitt WP, McNeish JD, Griffiths RJ, Nagahisa A, Nakane M, Amacher DE (2001). Induction of hepatic microsomal drug-metabolizing enzymes by inhibitors of 5-lipoxygenase (5-LO): studies in rats and 5-LO knockout mice. Toxicol Sci 63 : 15 21.
3. Bell RL, Young PR, Albert D, Lanni C, Summers JB, Brooks DW et al. (1992). The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol 14 : 505 510.
4. Berger W, De Chandt MT, Cairns CB (2007). Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract 61 : 663 676.
5. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 : 248 254.
6. 2. J Biol Chem 274 : 11660 11666.
7. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL et al. (1991). 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256 : 929 937.
8. de Carvalho MS, McCormack FX, Leslie CC (1993). The 85-kDa, arachidonic acid-specific phospholipase A2 is expressed as an activated phosphoprotein in Sf9 cells. Arch Biochem Biophys 306 : 534 540.
9. Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z et al. (2004). Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Cancer Res 10 : 6703 6709.
10. Chen X, Sood S, Yang CS, Li N, Sun Z (2006). Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention. Curr Cancer Drug Targets 6 : 613 622.
11. Collin M, Rossi A, Cuzzocrea S, Patel NS, Di Paola R, Hadley J et al. (2004). Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J Leukoc Biol 76 : 961 970.
12. Cuzzocrea S, Rossi A, Mazzon E, Di Paola R, Genovese T, Muià C et al. (2005). 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. Lab Invest 85 : 808 822.
13. Drazen JM, Israel E, O'Byrne PM (1999). Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340 : 197 206.
14. Dube LM, Swanson L, Awani WM, Bell RL, Carter GW (1998). Zileuton: the first leukotriene synthesis inhibitor for use in the management of chronic asthma. In : Drazen JM, Dahlen SE, Lee TH (eds). Lung Biology in Health and Disease. Marcel Dekker : New York, 391 pp.
15. Genovese T, Rossi A, Mazzon E, Di Paola R, Muià C, Caminiti R et al. (2008). Effects of zileuton and montelukast in mouse experimental spinal cord injury. Br J Pharmacol 153 : 568 582.
16. Gijón MA, Leslie CC (1999). Regulation of arachidonic acid release and cytosolic phospholipase A2 activation. J Leukoc Biol 65 : 330 336.
17. 2. J Cell Biol 145 : 1219 1232.
18. Gijón MA, Spencer DM, Siddiqi AR, Bonventre JV, Leslie CC (2000). Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that Do and Do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. J Biol Chem 275 : 20146 20156.
19. Gregor JI, Kilian M, Heukamp I, Kiewert C, Kristiansen G, Schimke I et al. (2005). Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster. Prostaglandins Leukot Essent Fatty Acids 73 : 89 97.
20. Hamad AM, Sutcliffe AM, Knox AJ (2004). Aspirin-induced asthma: clinical aspects, pathogenesis and management. Drugs 64 : 2417 2432.
21. Jakobsson PJ, Thorén S, Morgenstern R, Samuelsson B (1999). Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96 : 7220 7225.
22. Kane GC, Tollino M, Pollice M, Kimm CJ, Cohn J, Murray JJ et al. (1995). Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor. Prostaglandins 50 : 1 18.
23. Knospe J, Steinhilber D, Herrmann T, Roth HJ (1988). Picomole determination of 2,4-dimethoxyanilides of prostaglandins by high-performance liquid chromatography with electrochemical detection. J Chromatogr 442 : 444 450.
24. Kwak HJ, Park KM, Choi HE, Lim HJ, Parkm JH, Park HY (2010). The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKCdelta. Cell Signal 22 : 80 87.
25. Lazarus M, Kubata BK, Eguchi N, Fujitani Y, Urade Y, Hayaishi O (2002). Biochemical characterization of mouse microsomal prostaglandin E synthase-1 and its colocalization with cyclooxygenase-2 in peritoneal macrophages. Arch Biochem Biophys 397 : 336 341.
26. Li N, Sood S, Wang S, Fang M, Wang P, Sun Z et al. (2005). Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 11 : 2089 2096.
27. Liu MC, Dubé LM, Lancaster J (1996). Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol 98 : 859 871.
28. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 65 : 55 63.
29. Nunoshiba T, deRojas-Walker T, Wishnok JS, Tannenbaum SR, Demple B (1993). Activation by nitric oxide of an oxidative-stress response that defends Escherichia coli against activated macrophages. Proc Natl Acad Sci U S A 90 : 9993 9997.
30. Peters-Golden M, Brock TG (2000). Intracellular compartmentalization of leukotriene biosynthesis. Am J Respir Crit Care Med 161 : S36 S40.
31. Peters-Golden M, Henderson WR Jr. (2007). Leukotrienes. N Engl J Med 357 : 1841 1854.
32. 4in elicited mice peritoneal macrophages activated with lipopolysaccharide/ interferonγ. J Leukoc Biol 78 : 985 991.
33. Sautebin L, Ianaro A, Rombola L, Ialenti A, Sala A, Di Rosa M (1999). Cyclooxygenase-2-dependent generation of 8-epiprostaglandin F2α by lipopolysaccharide-activated J774 macrophages. Inflamm Res 48 : 503 508.
34. Seno K, Okuno T, Nishi K, Murakami Y, Watanabe F, Matsuura T et al. (2000). Pyrrolidine inhibitors of human cytosolic phospholipase A(2). J Med Chem 43 : 1041 1044.
35. Siemoneit U, Hofmann B, Kather N, Lamkemeyer T, Madlung J, Franke L et al. (2008). Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Biochem Pharmacol 75 : 503 513.
36. Specto AA (2009). Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 50 : 52 56.
37. Tacconelli S, Capone M, Sciulli M, Ricciotti E, Patrignani P (2002). The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin 18 : 503 511.
38. 4. Eur J Biochem 267 : 6428 6434.